Clinical Trial Update: A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

View source ↗

Summary

This is a post-marketing surveillance study in Korea evaluating Jakavi (ruxolitinib) for steroid-refractory graft-versus-host disease, and it is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Jakavi (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Graft-versus-Host Disease | Status: RECRUITING